Clinical trials: Vaccination
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study to Evaluate Impact of School-based Influenza Vaccination on School Populations
Rates of confirmed influenza illness in vaccinated and non-vaccinated children will be compared between schools with and without vaccination programs.
- Trial name
- NCT00844051
- Testing
- School-based influenza vaccination program
- Where
- 2 sites in United States
- Volunteers
- 4,455 people
- Sponsor
- Children's Hospital Los Angeles
Preventable Disease, Vaccine, Health Care Utilization
Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of MMR Vaccination
Our objective is to determine the effectiveness of varied outreach methods (e.g. automated reminder calls/text messages with or without personalized calls/texts) to children age 12-14 months or 4 years old who are due for a WCC…
- Trial name
- NCT04567342
- Testing
- 1 automated message, 2 automated messages, No personal contact attempt
- Where
- United States
- Volunteers
- 1,312 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
COVID-19
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a…
- Trial name
- CONCOR-1 (NCT04348656)
- Testing
- Convalescent plasma
- Where
- 73 sites in United States, Brazil and 1 more
- Volunteers
- 940 people
- Sponsor
- Hamilton Health Sciences Corporation
Healthy Aging
Beta-glucan and Immune Response to Influenza Vaccine
This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.
- Trial name
- M-Unity (NCT05074303)
- Testing
- Influenza Vaccine, Beta-glucan
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Florida
Respiratory Disorders
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune…
- Trial name
- NCT03281876
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 67 sites in United States, Belgium and 6 more
- Volunteers
- 606 people
- Sponsor
- GlaxoSmithKline
Prostatic Neoplasms, Neoplasms of Prostate
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Background: Few studies or literature are available about the long-term safety of repeated peptide vaccinations in people over a period of time. Long-term vaccination may be needed to control tumors.
- Conditions
- Prostatic Neoplasms, Neoplasms of Prostate, Prostate Cancer, Cancer Of Prostate
- Trial name
- NCT02362464
- Testing
- Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Hantavirus Pulmonary Infection, Immunisation
Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
This is a Phase 1, randomized, placebo controlled, double-blind, dose escalation trial of 48 males and non-pregnant females, 18-49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03682107
- Testing
- Andes virus DNA vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
This Phase 2 study aims to improve preparedness for future Ebola outbreaks by vaccination of a well-known population at risk, ie, a cohort of health care providers (HCP) (such as primary, emergency, and community health care…
- Trial name
- EBOVAC3DRC (NCT04186000)
- Testing
- Ad26.ZEBOV vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
HIV Exposure, HIV Infection
Early Versus Delayed BCG Vaccination of HIV-exposed Infants
In sub-Saharan Africa (SSA), more than 300,000 babies with HIV die each year. HIV-infected children develop AIDS and die faster in SSA than those in developed countries.
- Trial name
- NCT02062580
- Testing
- BCG
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Poliomyelitis, Tetanus
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine
This study evaluates the immunogenicity and safety of Infanrix hexa™ (DTPa-HBV-IPV/Hib) when administered as a primary vaccination course to Indian infants according to a 6-10-14 weeks or a 2-4-6 months schedule.
- Conditions
- Poliomyelitis, Tetanus, Acellular Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT01353703
- Testing
- Infanrix hexa™
- Where
- 4 sites in India
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis, Tetanus
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine
This study is designed to evaluate the safety and immunogenicity of Infanrix™-IPV+Hib vaccine when administered as a primary vaccination course to healthy Korean infants at 2, 4 and 6 months of age.
- Conditions
- Poliomyelitis, Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT01309646
- Testing
- Infanrix™-IPV+Hib, Infanrix™ IPV, Hiberix™
- Where
- 11 sites in South Korea
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Breast Cancer Related Lymphedema, Covid19
Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery.
- Trial name
- LymphVAX (NCT04872738)
- Testing
- Survey
- Where
- United States
- Volunteers
- 714 people
- Sponsor
- Massachusetts General Hospital
Infections, Meningococcal
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects
The purpose of this study is to demonstrate, in 11-17 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.
- Trial name
- NCT00464815
- Testing
- Meningococcal vaccine GSK134612, Mencevax™ ACWY
- Where
- 7 sites in India, Philippines and 1 more
- Volunteers
- 1,025 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Haemophilus Influenzae Type b, Neisseria Meningitidis
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine
This study is evaluating the safety and immunogenicity of GSK Biologicals' Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, each administered at 2, 4, and 6 months of age, and compared to…
- Trial name
- NCT00129129
- Testing
- GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix
- Where
- 27 sites in United States
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere
This study is to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines.
- Trial name
- NCT01306253
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Smallpox
ACAM 3000 MVA at Harvard Medical School
The purpose of this study is to assess the safety of an experimental smallpox vaccine (MVA: Modified Vaccinia Ankara) and to compare the body's immune (system that fights disease) response to this vaccine.
- Trial name
- NCT00133575
- Testing
- MVA Smallpox Vaccine, Live vaccinia virus vaccine
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Efficacy of the New CPRV
Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
Pre exposure rabies vaccination with a new Chromatographically Purified Vero-cell Rabies Vaccine(SPEEDA) is as effective as Purified Vero-cell Rabies vaccine.
- Trial name
- NCT01603875
- Testing
- New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).
- Where
- Thailand
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Dysentery, Bacillary
A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study
GVGH Shigella Sonnei 1970GAHB is a vaccine aimed at preventing the disease caused by Shigella sonnei. A post-hoc analysis of subjects who participated in the parent study showed significantly different responses in subjects with…
- Trial name
- NCT03089879
- Testing
- GVGH Shigella sonnei 1790GAHB vaccine
- Where
- France
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Escherichia Coli Infection
Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea
The purpose of the study is to determine if immunization with a chimeric E. coli protein, dsc14CfaE-sCT2/LTB5, is safe and immunogenic when administered by vaccination under the skin.
- Trial name
- NCT01644565
- Testing
- Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5, Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command